导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.40% | 2522/4773 |
| 近一周 | -2.61% | 4088/5465 |
| 近一月 | -7.18% | 4485/5421 |
| 近一季 | -14.33% | 4288/5231 |
| 近半年 | -2.79% | 2277/4920 |
| 近一年 | 2.01% | 2372/4394 |
| 近两年 | 74.78% | 932/2954 |
| 近三年 | 51.09% | 541/2253 |
| 成立以来 | 2.91% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.78% 2480/4961 |
21.74% 1160/5312 |
- - |
- - |
| 2025 | 32.67% 1168/4813 |
2.85% 1249/3635 |
-0.31% 2881/4076 |
32.27% 1086/4524 |
-2.18% 3103/4813 |
| 2024 | 21.17% 420/3463 |
0.11% 1038/2808 |
-1.83% 1113/3014 |
21.02% 633/3129 |
1.87% 1013/3463 |
| 2023 | -11.38% 1398/2656 |
7.06% 608/2280 |
-2.05% 557/2385 |
-10.18% 1969/2515 |
-5.91% 1552/2655 |
| 2022 | -27.73% 1502/2207 |
-20.52% 1554/1919 |
7.03% 546/2016 |
-17.90% 1656/2113 |
3.48% 688/2208 |
| 2021 | - - |
- - |
- - |
-7.43% 1051/1466 |
2.91% 498/1822 |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 永赢深证创新100ETF VS. 长安沪深300非周期A(740101) |